Research Driven by Clinical Need
Chronic wounds affect roughly 2 % of the general population of the United States. Healing these wounds is critical to increasing the likelihood that the patient can recover from the underlying conditions while decreasing the risk of local and systemic infection, reducing risk of amputation, and improving overall quality of life.
Surgical site infections occur after 2-5 % of surgeries resulting in morbidity, increased hospital length of stay, and increased costs. Reducing these infections improves quality of life for the patients and decreases associated costs.
Rochal has created innovative antimicrobial technologies for mitigation of microbial colonization and biofilm control.
The science for these technologies draws on synergy between fundamental chemical and biological actions. Continuing research focuses on specific microbiome environments and surrounding conditions.